$ANIK
Anika Therapeutics, Inc.

2012 Q3 Form 10-Q Financial Statement

#000115752312005906 Filed on November 08, 2012

View on sec.gov

Income Statement

Concept 2012 Q3 2012 Q2 2011 Q3
Revenue $14.77M $19.62M $18.46M
YoY Change -19.99% 21.58% 33.06%
Cost Of Revenue $7.221M $8.084M $7.395M
YoY Change -2.35% 21.46% 21.03%
Gross Profit $6.834M $10.80M $10.36M
YoY Change -34.04% 23.28% 33.52%
Gross Profit Margin 46.28% 55.02% 56.14%
Selling, General & Admin $3.602M $4.109M $4.712M
YoY Change -23.57% -2.95% 20.52%
% of Gross Profit 52.7% 38.05% 45.48%
Research & Development $1.217M $1.298M $1.531M
YoY Change -20.52% -17.53% -13.48%
% of Gross Profit 17.81% 12.02% 14.78%
Depreciation & Amortization $1.180M $1.190M $1.000M
YoY Change 18.0% 16.67% 25.0%
% of Gross Profit 17.27% 11.02% 9.65%
Operating Expenses $4.819M $5.407M $6.244M
YoY Change -22.82% -6.9% 9.92%
Operating Profit $2.727M $6.134M $4.817M
YoY Change -43.4% 66.79% 131.6%
Interest Expense -$45.16K -$49.13K -$46.27K
YoY Change -2.39% 8.5% 15.67%
% of Operating Profit -1.66% -0.8% -0.96%
Other Income/Expense, Net
YoY Change
Pretax Income $2.682M $6.085M $4.771M
YoY Change -43.79% 67.52% 133.88%
Income Tax $1.036M $2.348M $1.795M
% Of Pretax Income 38.65% 38.59% 37.61%
Net Earnings $1.645M $3.737M $2.977M
YoY Change -44.73% 63.71% 152.25%
Net Earnings / Revenue 11.14% 19.04% 16.13%
Basic Earnings Per Share $0.12 $0.28 $0.23
Diluted Earnings Per Share $0.11 $0.26 $0.22
COMMON SHARES
Basic Shares Outstanding 13.29M shares 13.26M shares 12.82M shares
Diluted Shares Outstanding 14.46M shares 14.44M shares 13.77M shares

Balance Sheet

Concept 2012 Q3 2012 Q2 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.90M $37.90M $29.00M
YoY Change 37.59% 41.42% 12.4%
Cash & Equivalents $39.86M $37.91M $29.05M
Short-Term Investments
Other Short-Term Assets $3.300M $3.200M $4.000M
YoY Change -17.5% -28.89% -4.76%
Inventory $8.932M $10.78M $7.900M
Prepaid Expenses
Receivables $16.34M $17.69M $17.70M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $68.40M $69.60M $58.60M
YoY Change 16.73% 21.04% 8.32%
LONG-TERM ASSETS
Property, Plant & Equipment $35.94M $36.42M $36.70M
YoY Change -2.08% -1.3% 0.82%
Goodwill $8.819M $8.628M
YoY Change
Intangibles $21.46M $21.51M
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $300.0K
YoY Change -33.33% -50.0% -84.21%
Total Long-Term Assets $66.47M $66.78M $71.20M
YoY Change -6.64% -9.64% -6.07%
TOTAL ASSETS
Total Short-Term Assets $68.40M $69.60M $58.60M
Total Long-Term Assets $66.47M $66.78M $71.20M
Total Assets $134.9M $136.4M $129.8M
YoY Change 3.91% 3.79% -0.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.908M $3.941M $3.800M
YoY Change -49.8% -48.14% -58.7%
Accrued Expenses $4.389M $4.276M $5.500M
YoY Change -20.2% -22.26% 12.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.600M $1.600M $1.600M
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $12.15M $15.21M $15.10M
YoY Change -19.5% -12.56% -17.49%
LONG-TERM LIABILITIES
Long-Term Debt $8.400M $8.800M $10.00M
YoY Change -16.0% -15.38% -13.79%
Other Long-Term Liabilities $1.539M $1.535M $4.900M
YoY Change -68.59% -76.01% -36.36%
Total Long-Term Liabilities $9.939M $10.34M $14.90M
YoY Change -33.29% -38.48% -22.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.15M $15.21M $15.10M
Total Long-Term Liabilities $9.939M $10.34M $14.90M
Total Liabilities $22.09M $25.55M $36.90M
YoY Change -40.12% -36.6% -18.9%
SHAREHOLDERS EQUITY
Retained Earnings $41.55M $39.90M
YoY Change
Common Stock $138.0K $137.7K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $103.5M $100.7M $92.90M
YoY Change
Total Liabilities & Shareholders Equity $134.9M $136.4M $129.8M
YoY Change 3.91% 3.79% -0.08%

Cashflow Statement

Concept 2012 Q3 2012 Q2 2011 Q3
OPERATING ACTIVITIES
Net Income $1.645M $3.737M $2.977M
YoY Change -44.73% 63.71% 152.25%
Depreciation, Depletion And Amortization $1.180M $1.190M $1.000M
YoY Change 18.0% 16.67% 25.0%
Cash From Operating Activities $2.210M $5.220M $2.980M
YoY Change -25.84% -472.86% -9.7%
INVESTING ACTIVITIES
Capital Expenditures -$140.0K -$930.0K -$290.0K
YoY Change -51.72% 60.34% -64.2%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$140.0K -$930.0K -$290.0K
YoY Change -51.72% 60.34% -63.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -160.0K -360.0K -400.0K
YoY Change -60.0% 28.57% 0.0%
NET CHANGE
Cash From Operating Activities 2.210M 5.220M 2.980M
Cash From Investing Activities -140.0K -930.0K -290.0K
Cash From Financing Activities -160.0K -360.0K -400.0K
Net Change In Cash 1.910M 3.930M 2.290M
YoY Change -16.59% -273.89% 9.05%
FREE CASH FLOW
Cash From Operating Activities $2.210M $5.220M $2.980M
Capital Expenditures -$140.0K -$930.0K -$290.0K
Free Cash Flow $2.350M $6.150M $3.270M
YoY Change -28.13% -850.0% -20.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13812747 shares
CY2012Q2 us-gaap Goodwill
Goodwill
8627518
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29048664
CY2012Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
464442
CY2012Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
5655726
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12154927
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2012Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
452140
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q3 us-gaap Assets Current
AssetsCurrent
68402277
CY2012Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
1600000
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-3353212
CY2012Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
256000
CY2012Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1450843
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2866667
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1351403
CY2012Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52141685
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1907564
CY2012Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1391694
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
41546458
CY2012Q3 us-gaap Assets
Assets
134872136
CY2012Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6435148
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000 shares
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134872136
CY2012Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16343600
CY2012Q3 us-gaap Inventory Net
InventoryNet
8932492
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13804975 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
138049
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39855856
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2869440
CY2012Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
21464089
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
35937469
CY2012Q3 us-gaap Goodwill
Goodwill
8818920
CY2012Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1918926
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65142128
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13804975 shares
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2600000
CY2012Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
585810
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4389002
CY2012Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1825923
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Long Term Debt
LongTermDebt
10000000
CY2012Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16204216
CY2012Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2172045
CY2012Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8400000
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
103473423
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
63441433
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1918926
CY2012Q3 us-gaap Debt Instrument Interest Rate At Period End
DebtInstrumentInterestRateAtPeriodEnd
0.0164 pure
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1539198
CY2012Q3 anik Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
249381
CY2012Q3 anik Intangible Assets Accumulated Amortization
IntangibleAssetsAccumulatedAmortization
5634820
CY2012Q3 anik Intangible Assets Gross Carrying Amount
IntangibleAssetsGrossCarryingAmount
30098000
CY2012Q3 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber
1900000 shares
CY2012Q3 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice
8.20
CY2012Q3 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue
13300000
CY2012Q3 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
1179007
CY2009Q4 us-gaap Area Of Land
AreaOfLand
26000 sqft
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28201932
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4091366
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14538423
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1052058
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
334473
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1831127
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
50850630
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4299680
CY2011Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
450482
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-3067181
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1503565
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2866667
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
34252221
CY2011Q4 us-gaap Assets
Assets
132844434
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
7375141
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000 shares
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132844434
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17307786
CY2011Q4 us-gaap Inventory Net
InventoryNet
7302483
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13630607 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
136305
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35777222
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5019440
CY2011Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23148563
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36469878
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Assets Current
AssetsCurrent
64137544
CY2011Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1600000
CY2011Q4 us-gaap Goodwill
Goodwill
8883407
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13630607 shares
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
457764
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5321594
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1707552
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Long Term Debt
LongTermDebt
11200000
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14380752
CY2011Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2498492
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9600000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
94762778
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1548652
CY2011Q4 anik Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
205042
CY2011Q4 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
1313280
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
151770
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12744471 shares
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
2103508
us-gaap Operating Income Loss
OperatingIncomeLoss
9051617
us-gaap Share Based Compensation
ShareBasedCompensation
901619
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.374 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-162997
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1884307
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
846732
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-953952
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2721155
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
768731
us-gaap Inventory Write Down
InventoryWriteDown
642120
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-516647
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12989268
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3335576
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-16899
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1116456
us-gaap Cost Of Goods Sold
CostOfGoodsSold
19655288
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5760 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
985364 shares
us-gaap Net Income Loss
NetIncomeLoss
5583570
us-gaap Costs And Expenses
CostsAndExpenses
37282731
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6352301
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1629264
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
44230840
dei Entity Registrant Name
EntityRegistrantName
ANIKA THERAPEUTICS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-454804
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
953952
us-gaap Sales Revenue Net
SalesRevenueNet
46334348
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
151770
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0151 pure
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13729835 shares
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1048230
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
901619
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8919146
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1057096 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4638175
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
51152
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1368665
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0119 pure
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6252826
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-17224
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2865813
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-132471
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2943295
anik Percentage Of Net Revenue
PercentageOfNetRevenue
1.00 pure
anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue
628007
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
ANIK
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0000898437
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
331639
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13237629 shares
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
2200995
us-gaap Operating Income Loss
OperatingIncomeLoss
11923690
us-gaap Share Based Compensation
ShareBasedCompensation
914003
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
135353
us-gaap Goodwill Translation Adjustments
GoodwillTranslationAdjustments
-64487
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.381 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-25496
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2150000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4078634
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1292487
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-716874
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-286031
us-gaap Inventory Write Down
InventoryWriteDown
790379
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
us-gaap Nature Of Operations
NatureOfOperations
<div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"> <div> <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td align="left" valign="top" width="5%"> <div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> 1.</font></div> </td> <td valign="top" width="95%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"> Nature of Business</font></div> </td> </tr> </table> </div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Anika Therapeutics,&#xA0;Inc. (together with its subsidiaries, &#x201C;Anika,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;us,&#x201D; or &#x201C;our&#x201D;) develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (&#x201C;HA&#x201D;), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.</font></div> <div style="TEXT-INDENT: 0pt; DISPLAY: block"><br /></div> <div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with the U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) and foreign regulations and approval requirements as well as the ability to grow the Company&#x2019;s business.</font></div> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
194000 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2433367
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11061256
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4483960
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
46390
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1012571
us-gaap Cost Of Goods Sold
CostOfGoodsSold
21718735
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5760 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1120162 shares
us-gaap Net Income Loss
NetIncomeLoss
7294237
us-gaap Costs And Expenses
CostsAndExpenses
36828350
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
456796
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7008206
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1517285
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
46551045
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-429718
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1292487
us-gaap Sales Revenue Net
SalesRevenueNet
48752040
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
331639
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0064 pure
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14357791 shares
us-gaap Tax Benefit From Stock Options Exercised1
TaxBenefitFromStockOptionsExercised1
-456796
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-411565
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
914003
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11778197
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
104187 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4048359
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-873153
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1398008
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0063 pure
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2399999
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4771093
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1674331 shares
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1531355
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-6318
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1036349
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7221028
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5736296
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-145493
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3364432
anik Share Based Compensation Arrangement By Share Based Payment Award Contractual Term Range
ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermRange
P10Y
anik Percentage Of Net Revenue
PercentageOfNetRevenue
1.00 pure
anik Dilutive Securities Excluded From Computation Of Earnings Per Share Amount
DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000 shares
anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue
1643502
anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingWeightedAverageRemainingContractualTerm
P4Y9M7D
anik Intangible Assets Translation Adjustments
IntangibleAssetsTranslationAdjustments
-2999091
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12817910 shares
CY2011Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
699817
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
4817362
CY2011Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.376 pure
CY2011Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1576131
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
CY2011Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4712178
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1794575
CY2011Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7394922
CY2011Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
947623 shares
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
2976518
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
13638455
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1400387
CY2011Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
547448
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2011Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
17756000
CY2011Q3 us-gaap Sales Revenue Net
SalesRevenueNet
18455817
CY2011Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13765533 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13287463 shares
CY2011Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-46269
CY2011Q3 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1.00 pure
CY2012Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
711171
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2726760
CY2012Q3 us-gaap Goodwill Translation Adjustments
GoodwillTranslationAdjustments
191402
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
319312
CY2012Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.386 pure
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2012Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
557712
CY2012Q3 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1.00 pure
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
75000 shares
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3601737
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5760 pure
CY2012Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1171691 shares
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
1645250
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
12039851
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0063 pure
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2202962
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
494301
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
14055440
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
14766611
CY2012Q3 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
184606
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14459154 shares
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
280930
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2681599
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
133064 shares
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1217086
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-45161

Files In Submission

Name View Source Status
0001157523-12-005906-index-headers.html Edgar Link pending
0001157523-12-005906-index.html Edgar Link pending
0001157523-12-005906.txt Edgar Link pending
0001157523-12-005906-xbrl.zip Edgar Link pending
a50464791.htm Edgar Link pending
a50464791ex31-1.htm Edgar Link pending
a50464791ex31-2.htm Edgar Link pending
a50464791ex32-1.htm Edgar Link pending
anik-20120930.xml Edgar Link completed
anik-20120930.xsd Edgar Link pending
anik-20120930_cal.xml Edgar Link unprocessable
anik-20120930_def.xml Edgar Link unprocessable
anik-20120930_lab.xml Edgar Link unprocessable
anik-20120930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending